Renaissance Technologies LLC Purchases 21,723 Shares of Xencor, Inc. (NASDAQ:XNCR)

Renaissance Technologies LLC increased its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 49.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,323 shares of the biopharmaceutical company’s stock after buying an additional 21,723 shares during the quarter. Renaissance Technologies LLC owned 0.11% of Xencor worth $1,237,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Xencor by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock worth $155,154,000 after purchasing an additional 243,793 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Xencor by 9.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after purchasing an additional 335,881 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Xencor by 6.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock worth $27,628,000 after buying an additional 87,979 shares during the period. Darwin Global Management Ltd. bought a new position in shares of Xencor in the first quarter valued at $24,557,000. Finally, Baker BROS. Advisors LP boosted its stake in Xencor by 122.2% during the 1st quarter. Baker BROS. Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock valued at $12,070,000 after purchasing an additional 300,000 shares during the last quarter.

Insider Buying and Selling

In other Xencor news, VP John R. Desjarlais sold 36,329 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total value of $665,547.28. Following the sale, the vice president now owns 192,319 shares in the company, valued at $3,523,284.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.23% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on XNCR shares. Raymond James decreased their target price on Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research report on Friday, June 14th. JPMorgan Chase & Co. decreased their price objective on Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price target on shares of Xencor in a research note on Monday, September 9th. Royal Bank of Canada raised their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $32.00 price target on shares of Xencor in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.78.

Xencor Trading Up 1.9 %

NASDAQ:XNCR opened at $19.85 on Friday. The business has a fifty day moving average price of $18.55 and a 200-day moving average price of $20.21. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -9.06 and a beta of 0.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92. Xencor, Inc. has a one year low of $15.31 and a one year high of $26.84.

Xencor (NASDAQ:XNCR) last released its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.25). Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. The company had revenue of $16.96 million during the quarter, compared to analysts’ expectations of $21.13 million. During the same period last year, the firm posted ($0.37) EPS. Xencor’s quarterly revenue was down 62.7% compared to the same quarter last year. Sell-side analysts forecast that Xencor, Inc. will post -4.15 EPS for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.